Prostate Cancer

Susan F. Slovin, MD, PhD, discusses the multinational PRONOUNCE study and how the results may affect the treatment of patients with prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses enzalutamide (Xtandi) for patients with nonmetastatic castration-resistant prostate cancer.

Leonard Gomella, MD, shares his insight on the recent FDA approvals and other ongoing progress in the treatment of patients with prostate cancer.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the difference between GnRH antagonists and GnRH agonists.

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses challenges with immunotherapy in prostate cancer.

Investigators looking for a superior means of testing for response to therapy in metastatic castration-resistant prostate cancer said they found the solution in a study of circulating tumor cells.

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

The use of androgen deprivation therapy in prostate cancer is now a well-established treatment regimen but is associated with an increased risk for bone fracture.

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service at the National Cancer Institute, discusses the take-home message with the combination of olaparib (Lynparza) plus durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

The FDA has approved apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).

William K. Oh, MD, discusses treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play.

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses a phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Christopher Sweeney, MBBS, discusses the role of abiraterone for patients with hormone-sensitive prostate cancer, and what physicians should consider when choosing between abiraterone and docetaxel.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service, at the National Cancer Institute, discusses a phase II study of olaparib (Lynparza) and durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer (mCRPC) in an unselected patient population, presented at the 2018 Genitourinary Cancers Symposium.

Data from the first 13 evaluable patients enrolled in a phase II study of SM-88 showed a reduction in circulating tumor cells, a slowing of prostate-specific antigen increase, and delayed radiographic progression of disease in nonmetastatic prostate cancer.

The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses 2 studies reported at the 2018 Genitourinary Cancers Symposium in patients with nonmetastatic M0 castration-resistant prostate cancer (CRPC).

The FDA has approved abiraterone acetate in combination with prednisone and androgen deprivation therapy for high-risk patients with metastatic hormone-naïve prostate cancer or newly-diagnosed metastatic hormone-sensitive prostate cancer.